Oral deucrictibant for on-demand treatment of hereditary angioedema attacks (RAPIDe-1): a randomised, double-blind, placebo-controlled, phase 2 trial

Marcus Maurer(Humboldt-Universität zu Berlin), Emel Aygören-Pürsün(Goethe University Frankfurt), Roman Hakl, Simone van Leeuwen(Roche (Netherlands)), Anne Lesage(Janssen (Belgium)), Jochen Knolle, Pavlína Králíčková(University Hospital Hradec Králové), Maria Staevska(Medical University of Sofia), Petra Staubach(Johannes Gutenberg University Mainz), David Hagin(University of Washington), O. Fain(Sorbonne Université), Michael Tarzi(Brighton and Sussex Medical School), Huaihou Chen(Covaris (United States)), Bruce Ritchie(University of Alberta), Aharon Kessel(Technion – Israel Institute of Technology), Rafael Crabbé, Maria Luisa Baeza(Hospital General Universitario Gregorio Marañón), Aurélie Du-Thanh(Centre Hospitalier Universitaire de Montpellier), Sorena Kiani-Alikhan(Royal Free London NHS Foundation Trust), Li Zhu(Covaris (United States)), Marie-Helene Jouvin(Covaris (United States)), Markus Magerl(Humboldt-Universität zu Berlin), Michael E Manning, Joshua S Jacobs(Allergy, Asthma and Clinical Research Center), Anna Valerieva(Alexandrovska Hospital), Danny M Cohn(Amsterdam University Medical Centers), John L. Anderson, Marcin Stobiecki(Jagiellonian University), Mar Guilarte(Vall d'Hebron Hospital Universitari), William H Yang(University of Ottawa), Ramon Lleonart(Bellvitge University Hospital), Marc A Riedl(UC San Diego Health System), Gordon L Sussman(University of Toronto), H Henry Li(Institute for Asthma and Allergy), Hugo Chapdelaine(Université de Montréal), Jens Greve, Laurence Bouillet(Centre National de la Recherche Scientifique), Giuseppe Spadaro(University of Naples Federico II), Avner Reshef(Barzilai Medical Center), Henriette Farkas(Semmelweis University), Peng Lü(Covaris (United States))
The Lancet Haematology
March 20, 2026
Cited by 4


Related Papers